Pulmonary Artery SarcomaNCT06165718
Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.
An observational study of Pulmonary Artery Sarcoma, run by China-Japan Friendship Hospital at 1 site in China.
Trial summary
This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Pulmonary Artery Sarcoma
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 31 Dec 2022to 30 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Pulmonary artery sarcoma patients expected to complete follow-up
Who may be able to join
- Computed tomography pulmonary angiography indicated that there were intraluminal defects
- Malignant histopathology was sarcoma
- Informed consent form was signed
Who cannot join
- Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma
- Expected inability to complete follow-up
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029
Wanmu Xie, +86 15611734410, xiewanmu@126.com
Wanmu Xie
About this study
Official title: A Multicenter, Observational Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.
This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.
Read the detailed description
This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.
- Conditions
- Pulmonary Artery Sarcoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free survival
Time to death or disease progression
Measured: 36 months
Secondary outcomes (2)
Overall survival
Time to death
Measured: 36 months
Postoperative survival
Time from surgery to death
Measured: 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2023
- Study start31 Dec 2022
- Primary completion31 Dec 2024 (estimated)
- Study completion30 Jun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Artery SarcomaStudies of the same condition, open and under way.
- More trials run by China-Japan Friendship HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- China-Japan Friendship Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- The First Affiliated Hospital of Guangzhou Medical University, Beijing Chao Yang Hospital, Shanghai Pulmonary Hospital, Shanghai, China, Sir Run Run Shaw Hospital, Beijing Anzhen Hospital
- Responsible party
- Principal investigator, Wanmu Xie, China-Japan Friendship Hospital
- Investigators
- Wanmu Xie, Principal investigator, China-Japan Friendship Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06165718
- Sponsor's protocol ID
- Roadmap for PAS-2022
- Status last verified
- Dec 2023
- First submitted
- 4 Dec 2023
- Last updated
- 15 Dec 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Observational Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.
- ClinicalTrials.gov ID
- NCT06165718
- Acronym / sponsor ID
- Roadmap for PAS-2022
- Conditions
- Pulmonary Artery Sarcoma
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- China-Japan Friendship HospitalUniversity, hospital or other
- Collaborators
- The First Affiliated Hospital of Guangzhou Medical University, Beijing Chao Yang Hospital, Shanghai Pulmonary Hospital, Shanghai, China, Sir Run Run Shaw Hospital, Beijing Anzhen Hospital
- Study start
- 31 Dec 2022 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 30 Jun 2025 (estimated)
- First posted
- 11 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.
Detailed description
This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Pulmonary artery sarcoma patients expected to complete follow-up
Key inclusion criteria (3 listed)
- Computed tomography pulmonary angiography indicated that there were intraluminal defects
- Malignant histopathology was sarcoma
- Informed consent form was signed
Key exclusion criteria (2 listed)
- Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma
- Expected inability to complete follow-up
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Progression-free survival
Time frame: 36 months
Time to death or disease progression
2 secondary outcomes
Overall survival
Time frame: 36 months
Postoperative survival
Time frame: 36 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Dec 2023.
Related trials for Pulmonary Artery Sarcoma
Not yet recruiting
CTEPH Differential Diagnosis Assisted by Enhanced Large Language Model Support
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Acute Pulmonary Embolism (PE)
RecruitingPhase 1/2
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Lung Cancer, Liver Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wanmu Xie principal investigator
China-Japan Friendship Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Artery Sarcoma, run by China-Japan Friendship Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Wanmu Xie (+86 15611734410, xiewanmu@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-free survival (time frame: 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Dec 2023.